TILT won a grant for a 2.5 M€ (~$ 2.9M) project, entitled UNLEASHAD, from the European Commission EIC SME Instrument. The grant will be used to perform a Phase 1 clinical trial with the company’s lead drug, TILT-123. Read the press release here.
Please contact our business development team to meet us at the following events:
Location: Boston (MA, USA)